Valneva (0OB3) Stock Overview
A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
0OB3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Valneva SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.06 |
| 52 Week High | €5.42 |
| 52 Week Low | €1.72 |
| Beta | 1.14 |
| 1 Month Change | 34.18% |
| 3 Month Change | 107.71% |
| 1 Year Change | 92.21% |
| 3 Year Change | -15.90% |
| 5 Year Change | -23.75% |
| Change since IPO | -37.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0OB3 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 19.0% | 9.0% | 2.2% |
| 1Y | 92.2% | 9.8% | 13.4% |
Return vs Industry: 0OB3 exceeded the UK Biotechs industry which returned 9.8% over the past year.
Return vs Market: 0OB3 exceeded the UK Market which returned 13.4% over the past year.
Price Volatility
| 0OB3 volatility | |
|---|---|
| 0OB3 Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0OB3's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0OB3's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 700 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
| 0OB3 fundamental statistics | |
|---|---|
| Market cap | €854.53m |
| Earnings (TTM) | -€67.04m |
| Revenue (TTM) | €196.33m |
Is 0OB3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0OB3 income statement (TTM) | |
|---|---|
| Revenue | €196.33m |
| Cost of Revenue | €176.97m |
| Gross Profit | €19.35m |
| Other Expenses | €86.40m |
| Earnings | -€67.04m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 20, 2025
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 9.86% |
| Net Profit Margin | -34.15% |
| Debt/Equity Ratio | 90.3% |
How did 0OB3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 15:44 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Valneva SE is covered by 23 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stéphan Dubosq | Arkeon Finance |
| Vladimira Urbankova | Erste Group Bank AG |
| Simon Scholes | First Berlin Equity Research GmbH |